Effective delivery of Pep-1-cargo protein into ischemic neurons and long-term neuroprotection of Pep-1-SOD1 against ischemic injury in the gerbil hippocampus

Neurochem Int. 2008 Mar-Apr;52(4-5):659-68. doi: 10.1016/j.neuint.2007.08.013. Epub 2007 Sep 1.

Abstract

We examined the intracellular delivery of Pep-1-cargo protein against transient ischemic damage in the hippocampal CA1 region in gerbils. For this study, we introduced green fluorescent protein (GFP) and constructed Pep-1-GFP protein. At 12h after Pep-1-GFP treatment, GFP fluorescence was shown in almost CA1 pyramidal neurons in ischemic animals; in the sham-operated group, GFP fluorescence was shown in a few pyramidal neurons. Next, we confirmed the long-term effects of Pep-1-Cu,Zn-superoxide dismutase 1 (SOD1) against ischemic damage. In behavioral test, locomotor activity was significantly increased in Pep-1- and Pep-1-SOD1-treated groups 1 day after ischemia/reperfusion; the locomotor activity in the Pep-1-treated group was higher than that of the Pep-1-SOD1-treated group. Thereafter, the locomotor activity in both groups was decreased with time. Four days after ischemia/reperfusion, the locomotor activity in the Pep-1-SOD1-treated group was similar to that of the sham group; in the Pep-1-treated group, the activity was lower than that of the sham group. In the histochemical study, the cresyl violet positive neurons in the Pep-1-SOD1-treated group were abundantly detected in the hippocampal CA1 region 5 days after ischemia/reperfusion. In biochemical study, SOD1 protein level and activity in all Pep-1-treated ischemic groups were significantly lower than that of the Pep-1-SOD1-treated group. Our results indicate that Pep-1-cargo fusion proteins can be efficiently delivered into neurons in the ischemic hippocampus, and that Pep-1-SOD1 treatment in ischemic animals show a neuroprotection in the ischemic hippocampus for a long time.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Brain / pathology
  • Brain Ischemia / drug therapy*
  • Brain Ischemia / pathology
  • Cell Death
  • Cysteamine / administration & dosage
  • Cysteamine / analogs & derivatives*
  • Cysteamine / pharmacology
  • Drug Delivery Systems
  • Gerbillinae
  • Green Fluorescent Proteins / metabolism
  • Hippocampus / pathology*
  • Ischemic Attack, Transient / drug therapy
  • Ischemic Attack, Transient / pathology
  • Male
  • Motor Activity / drug effects
  • Neurons / pathology*
  • Neuroprotective Agents*
  • Peptides / administration & dosage
  • Peptides / pharmacology*
  • Superoxide Dismutase / administration & dosage
  • Superoxide Dismutase / pharmacology*
  • Superoxide Dismutase-1

Substances

  • Neuroprotective Agents
  • Pep-1 peptide
  • Peptides
  • Green Fluorescent Proteins
  • Cysteamine
  • Superoxide Dismutase
  • Superoxide Dismutase-1